Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Liabilities and Shareholders Equity (2022 - 2025)

Praxis Precision Medicines has reported Liabilities and Shareholders Equity over the past 4 years, most recently at $937.9 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $937.9 million for Q4 2025, up 94.14% from a year ago — trailing twelve months through Dec 2025 was $2.3 billion (up 42.43% YoY), and the annual figure for FY2025 was $937.9 million, up 94.14%.
  • Liabilities and Shareholders Equity for Q4 2025 was $937.9 million at Praxis Precision Medicines, up from $396.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for PRAX hit a ceiling of $937.9 million in Q4 2025 and a floor of $87.9 million in Q4 2023.
  • Median Liabilities and Shareholders Equity over the past 4 years was $245.0 million (2022), compared with a mean of $309.7 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 58.92% in 2023 and later skyrocketed 449.31% in 2024.
  • Praxis Precision Medicines' Liabilities and Shareholders Equity stood at $115.1 million in 2022, then fell by 23.61% to $87.9 million in 2023, then skyrocketed by 449.31% to $483.1 million in 2024, then surged by 94.14% to $937.9 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $937.9 million (Q4 2025), $396.4 million (Q3 2025), and $452.8 million (Q2 2025) per Business Quant data.